ALBANY, N.Y. (AP) — When Alexis Kozmon and her husband decided to get a dog for their 6-year-old daughter, they chose to adopt rather than buy from a breeder to teach the child the value of rescuing.Four weeks later, the puppy the family named Sugar was dying painfully from distemper, and despite $3,000 in veterinary treatments, the only humane option was to put her down. Two of Sugar's siblings met the same fate. Kozmon faulted the volunteer-based rescue that had trucked the puppies from Texas, but when she complained to New York's consumer protection agency, she learned such groups are exempt from oversight."There was a loophole," said Kozmon, who lives in Middletown, Connecticut, but adopted from a group in southeastern New York.
NYS Entity Status
NYS Filing Date
MAY 15, 2013
NYS DOS ID#
NYS Entity Type
DOMESTIC BUSINESS CORPORATION
2013 - LUNA SIDING INC.
AROUND THE WEB
- Sick puppies spur New York scrutiny of non-profit rescues
By MARY ESCH, Associated Press - Sunday Aug 27, 2017
- The Hunt: A Private Roof Deck on the Upper West Side
By JOYCE COHEN - Thursday Jun 8, 2017
A couple wanted outdoor space, and found it, but at the top of a walk-up building.
- Neighborhood Joint: Tailoring in a Basement? It Suits Him
By SYLVIE BIGAR - Wednesday Jun 28, 2017
For 36 years, Bilal Egilmez, who learned his trade in Turkey, has altered and mended clothing at Genius Tailor, his Upper East Side shop.
- Tenement Museum in New York Names Its New President
By JOSHUA BARONE - Wednesday Jun 14, 2017
Kevin Jennings, a former nonprofit leader and Obama official, plans to expand the museum’s reach through virtual and augmented reality.
- Side Street: When Gentrification Knocks on the Wrong Door
By DAVID GONZALEZ - Tuesday Sep 5, 2017
Would-be buyers want Monxo Lopez’s South Bronx home, where an overheated real estate market seeks to remake — or erase — the past. He’s not selling.
- Considering the Side Effects of Drugmakers’ Money-Back Guarantees
By KATIE THOMAS and CHARLES ORNSTEIN - Monday Jul 10, 2017
The Trump administration is considering encouraging lowering drug costs through outcome-based contracts, but there is little evidence the approach works.